Ardelyx's XPHOZAH Study Results at Kidney Week: A Catalyst for Growth

Ardelyx (ARDX) shared new real-world data on its phosphate absorption inhibitor, XPHOZAH, at Kidney Week, sparking investor interest. The drug is the only FDA-approved therapy of its kind. Ardelyx's three-year total shareholder return is 214%, and shares have gained 15.5% in the past month. Analysts believe the company is undervalued at current levels, with a fair value of $11.73, nearly double the recent close of $5.81. Bullish forecasts for revenue gains, margin leaps, and profit multiples underpin the valuation. However, disruption in Medicare reimbursement or setbacks with Ardelyx's narrow product lineup could challenge the current outlook.